Global aptamers market dominated by North America

Press Release   •   Jul 18, 2013 10:14 BST

The global aptamers market has been forecast to increase at a compound annual growth rate (CAGR) of 49.24% over the next five years, increasing from a valuation of $287 million, to be worth a total of over $2.1 billion by 2018. Growth is forecast to be seen in all application areas, including therapeutics and disgnostics.

Aptamers is an emerging market, widely considered as a rival or substitute to antibodies in the scientific industry. Aptamers existed in parallel with antibodies for two decades, but its market potential was not utilised, even to a fraction of antibodies.

However, the achievement of Macugen has given a boost to the aptamer field. The list of promising aptamers in the clinical trials pipeline estimates that these synthetic chemical antibodies will soon surpass monoclonal antibodies in therapeutics, diagnosis, and imaging. With technological merits over antibodies, the aptamers market is poised to grow at par with antibodies in the next 10-15 years.

The global market for aptamers is expected to grow, backed by technological advancements with respect to selection processes and synthesis. The market will experience continuous improvements in aptamer synthesis and its applicability in drug discovery and routine research.

According to a recent report, 'Aptamers Market: Global Forecasts to 2018,' North America represents the largest contributor to the market, followed by Europe, due to the presence of technology providers and better R&D facilities.

The new markets that are expected to grow at a brisk pace are emerging economics such as China, India, Japan and other regions of Asia-Pacific and untapped markets of Europe due to their growing GDP, healthcare costs, and rising demand for safe and cost-effective diagnostics and therapeutics.

Key players currently dominating the global aptamers market include AM Biotechnologies, LLC (U.S.), Aptagen, LLC (U.S.), Aptamer Sciences Inc. (South Korea), Aptamer Solutions Ltd (U.K.), Base Pair Biotechnologies (U.S.), Bioapter S.L. (Spain), Integrated Biotechnologies, Inc. (U.S.), NOXXON Pharma AG (Germany), OTC Biotech (U.S.), Regado Biosciences, Inc. (U.S.), Somalogic, Inc. (U.S.), and TriLink BioTechnologies, Inc. (U.S.).

For more information on the global aptamers market, see the latest research: Aptamers Market Research

Follow us on Twitter @CandMResearch issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.